Drugs / Paclitaxel liposome
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 24 trials | ||||||
| Phase 2 | NCT07138755 | Aug 2025 → Dec 2028 expected | non-small cell lung carcinoma | The Third Xiangya Hospital of Central South University | Recruiting | No outcome recorded |
| Phase 2 | NCT05585580 | Mar 2023 → Apr 2026 overdue | gastroesophageal adenocarcinoma | Qilu Hospital of Shandong University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04644250 | Sep 2020 → Mar 2022 | esophageal squamous cell carcinoma | Wei Ren | Unknown | No outcome recorded |
| Phase 2 | NCT03020329 | Nov 2016 → Dec 2020 | nasopharyngeal carcinoma | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT04217096 | Jan 2020 → Sep 2022 | pancreatic neoplasm | Fudan University | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT04760431 Background | Oct 2021 → Sep 2024 | HER2 positive breast carcinoma, metastatic malignant neoplasm in the brain | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Paclitaxel liposome | “Paclitaxel Liposome: 135-175 mg/m2, administered by IV infusion every 3 weeks” NCT04760431 ↗5“Paclitaxel or Paclitaxel liposome 135-175mg/m2 D1 IV Q3W(Squamous）” NCT07138755 ↗ |
| Route | Intravenous | “Patients receive paclitaxel liposome 175 mg/m\^2 (iv, 3h)” NCT04217096 ↗ |